Research overview

Dr. Marsha A. Moses is the Julia Dyckman Andrus Professor at Harvard Medical School and the Director of the Vascular Biology Program at Boston Children's Hospital. She has made significant contributions to our understanding of the biochemical and molecular mechanisms that underlie the regulation of tumor growth and progression. Dr. Moses and her laboratory have discovered a number of inhibitors of neovascularization that function at both the transcriptional and translational level some of which are being developed for potential clinical use in a variety of human diseases. Named a pioneer in the field of Biomarker Medicine by the Journal of the National Cancer Institute, she created a Proteomics Initiative at Boston Children’s Hospital and has utilized its resources, including an extensive human biorepository and her significant expertise in proteomics, to discover and validate a number of novel, non-invasive, urinary biomarkers for a variety of human cancers as well as non-neoplastic diseases. A number of these biomarkers are being used in clinical trials. She and her team have also engineered novel non-toxic, targeted nanomedicines for the treatment of human cancers and their metastases. These drug delivery systems are engineered to deliver a variety of therapeutic agents including siRNAs, chemotherapies and gene editing systems. A number of these diagnostics and potential therapeutics are included in Dr. Moses’ significant patent portfolio composed of both US and foreign patents.


Dr. Moses’ basic and translational work has been published in such journals as Science, The New England Journal of Medicine, Cell, and Nature Communications, among others. Marsha received a Ph.D. in Biochemistry from Boston University and completed a National Institutes of Health postdoctoral fellowship at Boston Children's Hospital and MIT in the laboratory of Dr. Robert Langer. She is the recipient of a number of NIH and foundation grants and awards. Dr. Moses has been recognized with both of Harvard Medical School's mentoring awards, the A. Clifford Barger Mentoring Award (2003) and the Joseph B. Martin Dean’s Leadership Award for the Advancement of Women Faculty (2009). In 2014, she received the Excellence in Mentoring Award from the Postdoc Association of Boston Children’s Hospital and in 2016, she received their award for Exceptional Mentorship. In 2013, Dr. Moses received the Honorary Member Mentoring Award from the Association of Women Surgeons of the American College of Surgeons. Dr. Moses was elected to the Institute of Medicine (National Academy of Medicine) of the National Academies of the United States in 2008, the National Academy of Inventors in 2013 and the American Institute for Molecular and Biological Engineering in 2018.



About Marsha A. Moses

Dr. Moses received a Ph.D. in Biochemistry from Boston University and completed a National Institutes of Health postdoctoral fellowship at Boston Children's Hospital and MIT. She is the recipient of a number of NIH and foundation grants and awards. In 2013, Dr. Moses received the Honorary Member Award from the Association of Women Surgeons of the American College of Surgeons, and has also been recognized with both of Harvard Medical School's mentoring awards, the A. Clifford Barger Mentoring Award (2003) and the Joseph B. Martin Dean’s Leadership Award for the Advancement of Women Faculty (2009). Dr. Moses was elected to the Institute of Medicine (National Academy of Medicine) of the National Academies of the United States in 2008, the National Academy of Inventors in 2013 and the American Institute for Molecular and Biological Engineering in 2018.

Researcher Services

Researcher Programs

PUBLICATIONS

  • Jia D, Hasso SM, Chan J, D’Amore, Zurakowski D, Rodig SJ, Moses MA. Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. Blood 2013 Jan 24; 121(4): 707-15; Epub 2012 Dec 3. PMCID: PMC3557646 (*Selected for Cover Feature)
  • Yang J, McNeish B, Butterfield C, Moses MA. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J 2013; 27(1): 45-50. PMCID: PMC3528324 
  • Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotinen M, Hager MH, Insabato L, Moses MA, Demichelis F, Lisanti MP, Wu H, Klagsbrun M, Bhowmick NA, Rubin MA, D'Souza-Schorey C, Freeman MR. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol 2012 Nov;181(15):1573-84. PMCID: PMC3483805
  • Roy R, Rodig S, Bielenberg D, Zurakowski D, Moses MA. ADAM12 transmembrane and secreted isoforms promote breast tumor growth and metastasis. J Biol Chem 2011 Jun 10; 286(23); Epub 2011 Apr 14. PMCID: PMC3121517
  • Fernandez CA, Roy R, Lee S, Yang J, Panigrahy D, Van Vliet KJ, Moses MA. The anti-angiogenic peptide, Loop 6, binds IGF-IR. J Biol Chem 2010 Dec 31; 285(53); Epub 2010 Oct 12. PMCID: PMC3009916
  • Yang J, Bielenberg DR, Rodig SJ, Doiron R, Kung AL, Zurakowski D, Moses MA. Neutrophil gelatinase-associated lipocalin promotes breast cancer progression: mechanistic studies and clinical implications.  PNAS 2009; 106(10): 3913-3918. PMCID: PMC2656179
  • Harper J., Yan L., Louriero R., Wu I., Fang J., D'Amore P., Moses M.A. (2007) Repression of VEGF expression by the zinc finger transcription factor ZNF24. Cancer Res., 67(18):8736-41.
  • Pories S.E., Zurakowski D., Roy R., Lamb C.C., Raza S., Exarhopoulos A., Scheib R.G., Schumer S., Lenahan C., Borges V., Louis G.W., Anand A., Isakovich N., Hirschfield-Bartek J., Wewer U., Lotz M.M., Moses M.A. (2008) Urinary metalloproteinases: noninvasive biomarkers of breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev., 17(5):1034-42.
  • Smith E.R., Manfredi M., Scott R.M., Black P., Moses M.A. (2007) A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report. Neurosurgery, 60(6):E1148-9.

Article From Vector